Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Topline data were announced from two phase 3 trials evaluating MR-107A-02 for the treatment of moderate to severe acute pain.

Discontinuing PJP prophylaxis while on prednisone doses greater than 12.5 mg per day may elevate infection risk among patients with rheumatic diseases.

Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.

A low dose combination hormonal patch was found to be effective for pregnancy prevention based on results from a phase 3 study.

Results of the updated systematic review informing the 2024 EULAR recommendations showed that many ARDs are safe to use during pregnancy, lactation, and reproduction.

Individuals with type 2 diabetes or a higher BMI may face a reduced risk of developing GCA, while a history of cardiovascular disease may increase this risk.

The global burden of atopic dermatitis (AD) in older adults is considerable and is expected to continue increasing to 2050.

The use of HCQ among patients with SSc appears to be low and is not associated with improvements in hand function or activities of daily living.